Trade Mark Journal No.2021/053 31 December 2021
UK00003702919 28 September 2021 (1,5,42,44,45)
Medigene Immunotherapies
This case is filed pursuant to Article 59 of the Withdrawal Agreement between the United Kingdom and the European Union and the EU filing date was 28/10/2020
International priority date claimed: 28 October 2020
(European Union Intellectual Property Office (EUIPO))
(018327910)
- Class 1
- Nucleic acids.
- Class 5
- Medicines for humans and animals, Vaccines, Serums, Test kits and Diagnostic preparations, In particular manufactured using molecular biological, genetic engineering and biotechnological methods; proteins, Cell products, Protein conjugates, Peptides, Enzymes and enzyme preparations, In particular antibodies and T-cell proteins; T-cells, Dendritic cells and other immune system cells, viruses and Particles similar to viruses; Liposomes; Plant extracts; Low-molecular active substances; Medicines, Vaccines, Adjuvants, Serums, Test kits and Diagnostic agents relating to precancerous cells, benign and malignant tumours, in particular haematological tumours, inflammatory disorders, neurodegenerative disorders, Autoimmune conditions and Immunotherapy.
- Class 42
- Molecular biology and biotechnology laboratory services, In particular research and development in the field of medical and veterinary diagnosis and treatment using molecular biological, genetic engineering and biotechnological methods, and in the field of screening for pharmaceutically active components; Development of test procedures and test kits in the field of biotechnology and medicine.
- Class 44
- Medical analysis and medical consulting in connection with the treatment of individuals, In particular in the field of precancerous cells, benign and malignant tumours, autoimmune diseases and Immunotherapy.
- Class 45
- Licensing of intellectual property, Including trademarks and patents in the field of biotechnology, pharmacy and medicine.
Medigene Immunotherapies GmbH
Representative: Kilburn & Strode LLP